03 August 2021

Safety Alerts

Reference: CIR-2021-00000128

To all Health facilities / all health care practitioners in Dubai's private health sector

Referring to the above subject, DHA notifies all health facilities regarding the Circular issued by the MOHAP for perusal and adhere to what is stated

 

Safety update of a pharmaceutical product Tetralysal 300mg Hard Capsules

Lifting the Suspension of the Product Amlopress (Amlodipine) 5mg Capsules

Labelling update regarding the use of non-steroidal anti-inflammatory drugs (NSAIDs) beyond 20 weeks of pregnancy

Recall & change shelf life date on the Pharmaceutical Product label Xiidra (Lifitegrast) 5% Ophthalmic solution

Medical device Voluntary recall from the manufacturer basixALPHA™ Inflation Device

 

Thanks in advance for your good co-operation

Drug Control Sect

Health Regulation Sector

DHA

 

Supporting Documents:

Tetralysal 300mg Hard Capsules تحذير على منتج طبي-.pdf:

View Document

Amlopress (Amlodipine) 5mg Capsules رفع تعليق-.pdf:

View Document

(NSAIDs) beyond 20 weeks of pregnancy تحذير.pdf:

View Document

Xiidra (Lifitegrast) 5% سحب وتعديل تاريخ الانتهاء على ملصق المنتج الطبي.pdf:

View Document

basixALPHA™ Inflation Device تقارير السلامة لوسيلة طبية-1.pdf:

View Document